China’s biotechs on the move

For most of the last decade, big drug companies hunted for new medicines in Boston, Basel, and San Diego. In 2025 and early 2026, they started writing very large checks to Chinese biotech firms instead. (pfizer.com, scmp.com) A drug pipeline is just a queue of experimental medicines moving from lab work into human testing and, if they survive, onto pharmacy shelves. The company with the best queue 5 years early usually has the best sales 10 years later. (nature.com, nature.com) China changed the speed of that queue after a 2015 overhaul of its drug review system. The reforms cut approval backlogs, pushed cleaner trial data, and made it easier for companies to build around new drugs instead of copycat generics. (nature.com, academic.oup.com, nber.org) By 2015, China contributed about 160 compounds to the global pipeline of innovative drugs, or less than 6% of the total. A decade later, analysts at Nature Reviews Drug Discovery describe a full “decade of innovation” driven by new financing, returnee scientists, and faster development systems. (nature.com, nature.com) The pitch from China is simple: run more experiments, recruit patients faster, and spend less money getting to an answer. Bloomberg reported that Chinese firms are moving more cheaply and quickly from animal studies to human trials, which is exactly the stretch where Western drug research often burns cash. (bloomberg.com, businesstimes.com.sg) That is why Pfizer agreed in May 2025 to pay China’s 3SBio $1.25 billion upfront for rights outside China to SSGJ-707, a cancer drug aimed at two targets, Programmed Death-1 and Vascular Endothelial Growth Factor. Pfizer also agreed to up to $4.8 billion in milestone payments and a $100 million equity investment. (pfizer.com, money.usnews.com) A licensing deal is basically renting someone else’s unfinished house before the roof is on. The Western company pays now for the right to finish development, run global trials, and sell the drug later. (pfizer.com, nature.com) Pfizer is not alone. AstraZeneca signed one 2025 pact with CSPC Pharmaceuticals to discover oral drugs for chronic diseases and another 2026 obesity and diabetes collaboration that carried a $1.2 billion upfront payment and up to $3.5 billion more in milestones. (astrazeneca.com, pharmaceutical-technology.com) Merck and Novo Nordisk have been shopping there too. In 2025, Merck licensed a heart drug candidate from Jiangsu Hengrui, and Novo Nordisk bought rights to an obesity drug from United Laboratories in a deal worth up to $2 billion. (pamirllc.com, fiercepharma.com) The money flow shows this is not a one-off. Nature reported that 5 of the top 10 research and development licensing deals of 2025 involved China-based companies, and Jefferies said China accounted for 32% of global biotech out-licensing deal value in the first quarter of 2025, up from 21% in 2023 and 2024. (nature.com, fiercebiotech.com) By March 2026, the South China Morning Post reported that Chinese biotech out-licensing reached $60 billion in the first quarter alone. When drug companies that used to invent at home start importing early-stage science at that scale, the center of gravity is moving. (scmp.com, fiercebiotech.com) The risk is that many of these medicines are still early, and early drug bets fail all the time. The change is that China is no longer being treated as a cheap factory for pills; it is being treated as a source of the next blockbuster before the rest of the world can price it in. (nature.com, biopharmadive.com)